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Nonsense mutations in protein genes have been associated with a variety of 
human diseases. A useful therapeutic approach to correct such mutafions may be to 
inboduce genes expressing suppressor tRNA that recognize the premature stop codon, 
insert the appropriate amino acid, and allow translation of a MI-length, functional 
protein. Human opal arginine suppressor tRNA genes that encode the structural portion 
of the tRNA and about 15 bases from the 3' flanking sequence were synthetically 
constructed using oligonucleotides. Retroviral vectors were selected for delivery to 
human target cells in order to stably integrate the suppressor tRNA into the target cells' 
genome. Recombinant retroviral vectors were used to transfeet retrovirus packaging 
cells and produce recombinant viral supernatants. Recombinant viral supernatants were 
then used to transduce the target cells. Expression of suppressor tRNA in both the 
retrovims packaging cells and in the target cells was confirmed by slot blot analysis. To 
test the functional activity of the expressed suppressor tRNA, target cells expressing a 
nonsense mutated GFP reporter gene (Arg73opal mhRGFP) were transduced with the 
recombinant viral supernatant. Suppression of the opal nonsense mutation in hRCW was 
demonstrated by restoration of hRGFP fluorescence. This study suggests that retroviral 
vectors may be used to deliver suppressor tRNA genes to human target cells. 
A Part o f  Nature 
Sometimes we see a part of Nature 
meant for eyes of God alone, 
and as long as mercy meek shall be, 
thc moment is eternity, 
fbr as an eagle rises hungry in the blue 
o'er winter's oldest snows, 
so my thoughts from depths of day 
shall live again that view. 
Edward Eylar, Ph.D. 
from a c,oliection of  poems, REALITY AND DNA 
reprir~ted with kind permission of the author 
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INTROD$IJCrFHON 
Gene therapy describes the treatment of human disease by transferring genetic 
material into a patient. The genetic material may be either DNA or RNA intended for 
somatic or germ line therapy (Polvino and Anderson, 1996) Gene therapy directed 
towards the production of furlctional proteins could follow either of two a-pproaches. The 
treatment may introduce a norrnal gene or a gene with a therapeutic effect. 
In replacement therapy., a functional gene is introduced in the organism to 
complement the defective gene, thereby restoring the normai phenotype (Anderson, 1992). 
This approach has been tested in uitro and in vivo for a range of diseases such as 
adenosine dearninase deficiency (Rlaese et al.. 1095). Xeroderrna pigmentosum (Panchal 
et a]., 1 099), Cystic fibrosis (Yagi et a i ,  1998), and 7'ype 1 Diabetes (Gros et al., 1999). 
Genes with potential therapeutic effects are also being studied for use in the 
treatment of diseases. For example, suicide genes encoding prodrug-activating enzymes 
such as herpes simplex thymidine kinase in combination with the prodrug ganciclovir, are 
being studied for the treatment of colon adenocarcinoma (Nielsen et al.. 1997) Other 
strategies include the use of antisense oiigonuciotides, ribozymes, and cytokine gene 
therapy (Lattime and C;ersot~, 1999). 
The cloning and characterization of genes has revealed a wide spectrum of diseases 
that occur as a result of nonsense mutation (Atkinson and Martin, 1994). The 
international effort to map the human provides information for normai genotypes that can 
be utilized for development of therapeutic strategies for the disease phenotypes (Jonsen, 
i 996) proteins are normally translated from messenger kVA (mRNA) which have 
secluences coding for the structural portions of the protein followed by one of three 
tral~siation termination signals: amber (UAG), ocher (UAA), or opal (UGA) stop codons. 
Mutations in the portion of the mR1'A coding for the structural part of the protein which 
produce a premature termination signal are termed nonsense mutations As expected, this 
type of rnl.itation will ultimately cause premature termination of protein synthesis. The 
resulting truncated protein may have limited function or may not have any normal 
function. Gene therapy may play a role in the treatment of diseases resulting iiom 
nonsense mutations through the use of suppressor tRNA genes that are designed to 
recognize the nonsense codon. insert the amino acid which would be preser~t in the normal 
phenotype, and continue protein translation beyond the nonsense mutation. 
-The potential application of suppressor tRh'A for gene therapy was first 
demonstrated for fi-thalassaemia. Temple et al. (1 9823, coinjected the nuclei of  Xe110p11.~ 
Inevi.r oocytes with amber lysine suppressor tRNA and mRNA from a patient with P- 
thalassaemia. The suppressor tRNh was able to suppress the nonsense mutation in the P- 
globin gene and synthesize a hil-length p-globin gene product Arrother strategy used 
suppressor tRNA to coritrol the expression of the nonsense-mutated diphtheria toxin A 
gene in mammalian cells and thereby target ablation of cancerous tissues (Robinson and 
Maxwell, 1995). The iri v i w  application of suppressor tRNA for treatment of genetic 
disease caused by nonsense mutation was dernonstraied in an mdx mouse, an animal 
model for human Duchenne lrluscular dystrophy with ochre mutation in the dystrophin 
gene. Direct injection of plasmid DNA, encoding the ochre suppressor tRNA, into mdx 
mouse tissue p~oduced dystrophin positive fibers (Li et al., 1 997). 
A major challenge to the success of gene therapy is the development of safe and 
efficient delivery systems for the transfer of therapeutic gene(s) into target cells. To 
achieve this goal, various recombinant viral and non-viral delivery systems have been 
developed (Robbins and Ghivizzani, 1998). 
The aim of this study is to determine if recombinant retroviral vectors can be used 
as delivery vehicles to transfer opal arginine suppressor tRNA genes into human cells 
using accepted methods for replication-incompetent retrovirai vectors and packaging cell 
lines. 
Proj ect Ovewiew 
This it~vestigation began with the synthesis of opal arginine suppressor tmA 
genes The synthetic gene inserts were subcloned into a replication-incompetent retroviral 
vector, pLNXpL, I .  The recombinant vectors bearing plausible suppressor tRNA genes 
were identified by endnnuclease restr-lction analysis. After the initial screening, the vector 
constructs were tested for function using a nonsense-mutated reporter gene, humanized 
red-shifted green fluorescent protein (mNIGFP). Plasmid constructs bearing functional 
suppressor tRNA genes were verified by DNA sequencing. Retroviral vectors with 
fi~nctional suppressor tRNA geaes were transfected into an ecotropic packaging cell line, 
GP-+E-86, to produce viral particles (virions) capabie of i~~fectiny mouse cells. Virions 
produced by GPtE-80 were then used to transciuce a n  arnphotropic packaging cell line, 
['A3 17, to produce virions capable of transferring the therapeutic gene to human cells. A 
viral titer bioassay was used to monitor the production of virions by PA3 I 7 Supernatant 
containing virions was used to trarisduce human target cells in an attempt to stably 
integrate the suppressor tRNA gene in the host cells' genome Expression of opal arg 
suppressor tKN A genes in both the packaging cells artd in human target cells was 
evaluated by slot blot anaiysis. XP! 2KOSV human target cells were transfected with the 
mutated hRGFP gene artd then transduced with the viral supernatant produced by PA3 17 
cells. Restoration of GF'P fluorescence in the target cells would demonstrate suppression 
of opal nonserlse mutation and translation of a full-length, functional hRGFP protein. 
REVIEW OF THE LITERATBLJRE 
Transfer KNA (tRNA) are a class of molecules that mediate the insertion of amino 
acids into the nascent polypeptide chain by sequential ide~itification of codons on mRNA. 
Every ceii contains a set of tKNAs. each of which carry one of the 211 diRerent amino 
acids to the site of protein translation. 
Mature tR2NA.s are a small RNA molecules, usually 70 to 90 nucleotides in length. 
Nu~ieotides within each molecule have extensive hydrogen bonding to form a cloverleaf 
secondary structure of four helical segments and three !oops (Figure I) .  The ololecliie is 
hr ther  folded into at1 L-shape. tRNAs are transcribed by R N A  polymerase [TI and contain 
their own iritragenic split promoters that become a part of the mature tRNA coding 
sequence (Sharp e i  al, 1985; Geiduschek and Tocchini-Valentini, 1988). Two structural 
features of tRNA that are important in protein translation are the 3' amino acid acceptor 
stem and the trinucleotide anticodon loop. The 3 ' acceptor stan of the tRNh consis~s of 
four niicleotides in a single strand ending with CCPq,,,. .4n aminoacyl-tRNA synthetase 
iderrtiGes recognition elements on the structural portion of the tRNA and attaches a 
specific amino acid by ester linkage to the 3' adenosine of the CCA sequence (Saks et al., 
1994). The ant~codon loop is complementar~~ to the avino acid codon on mRNA with 
some flexibil-ity in base pairing (Schimrnd and Ribas de Pouplana, 1995). Sorne amino 
acids !lave more tlian one tRNA in order to acconlmodate the different mRNA codons for 
the sarnle amino acid. 
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Fiylre 1. The noncoding strand of the human arginine tRNA gene shown in cloverleaf 
formation (adapted from BucWand et al., 1996). 
Natural human tRNA genes are considerably larger than the mature structural 
form. The 5' and 3' flanking sequences appear to provide extragenic transcriptional 
Id and Gross (1987) described a positive control element between the -5 1 
and - 16 nucleotide positions which enhanced the formation of stable transcription 
complexes. In another study, Amold et al., 1988, subsequently observed that the 3' 
extragenic control element appeared to stimulate transcription of the tRNA by facilitating 
the transition of a preinitiation complex into an active transcription complex. 
The human arginine tRNA has been sequenced and mapped to the short arm of 
chromosome 6 using recombinant libraries (Buckland et al., 1996). There appears to be a 
cluster of low-copy tRNA genes, including methionine, alanine and arginine tRNA genes, 
in the 6p2 1.2-p22.3 region. The opal arg suppressor tRNA used in this study has a design 
based on the structural sequence of the human arginine tRNA gene. 
Suppressor lRNA 
Suppressor tRNAs are a form of tRNA that base pair with a termination codon in 
mRNA arld add an amino acid to what would have been the C terminus (carboxy 
terminus) of the nascent polypeptide chain. Translation of the protein is not terminated at 
the  stop codon, but instead, proceeds to one of the alternate stop codons on the mRNA. 
The suppressor tRNA are named on the basis of which type of stop codon is paired to the 
anticodon duritig translation: UAG (amber), OAA (ochre), or UCA (opalj. 
Suppressor tRNAs are known to occur naturally in both prokalyotes and some 
elikaryotes. There has been extensive characterization of suppressor tRNG in bacteria., 
yeast, and ciliate protozoa. In Saccharomj~ces cevevisiae, glutamine suppressor tRNA are 
found to suppress amber and ocher stop codons (Weiss et al., 1987). Early studies 
(Kuchino et ai., 1 985; Hanyu et al,, 1986) suggest that glutarnine tRNA may be an 
evolutionary progenitor of amber suppressor t RNA. Amber or ocher glutamine 
suppressor tRNA are found in T~f~'whjfrflenir fhe mophila. Their findings indicate that 
there are three types of glutamine tRNA: two recognize the norrnal CAA and CAG 
codons for glutamine, the third recognizes both UAA and UAG stop codons 
Mammalian suppressor t W A s  have been described. Valle et at. (1987) isolated 
amber leucine t RNA from calf liver. Kuchino and Mur amatsu ( 1996) isolated amber 
glutamine suppressor tRNA from mouse and rat livers. They described conditional 
suppression when unique pseudoknot structures, required for nonsense suppression, were 
present in rnRNA. 
'The hurnan genome has been screened for nztturally occurring suppressor tRNA. 
O'Neil (1 085) described an opal serine suppressor tRNA from a human DNA libray 
which was detected by an opal suppresscbr tRNA probe. Opal serine suppressor tRNAs 
have been found in mouse, bovine, and human tissues (Hatfield et al., 1990) 
'To date, a review of the literature does not reveal any naturally occurring human 
opal arginine suppressor tRNA i n  addition, a database search of the Online Mendelian 
Inheritance in Man revealed more than 200 reports of an argirline to opal mutation in 
genes. thereby leading to disease conditions. This finding appears to support the 
probability that opal arginine suppressor tRNAs are not naturally found in the human 
genome. i n  addition, the cataloging and characterization of the genetic basis for these 
diseases reaffirms the need for- therapeutic intervention. 
Functional suppressor tRNA could be either the hll-length gene of about 800 
nucleotides that include the 5' and 3' flanking sequences or only the rnature form of about 
100 n~;cleotides. Different suppressor tRNAs could be constructed using oligonucleotide 
site-specific nlutagenesis to change one or two nucleotides in the anticodon of the cloned 
tRNA gene (Capone et al., 1985). Arrlber phenylalanine and amber cysteine suppressor 
genes were synthetically constructed using four to six oligonucleotides (Normanly et al., 
1986) These genes did not contain the 4' and 3' flanking sequences, however, they were 
able to suppress an amber mutation in the dihydrofolate reductase protein gene in E- coli. 
Both the full-length and the mature form of the suppressor tRNA genes would be within 
the size limitations of a retroviral vector system. 
Retrsviral vectors 
The production of a hnctional protein from a gene with a nonsense mutation 
would benefit from long-term expression of a therapeutic suppressor t W A  For this 
study, recombinant retroviral vectors were selected as delivery vehicles because they have 
been shown to stably integrate the therapeutic gene into human somatic cells 
(Morgm"sern and Land, 1991 ). 
The retroviral vector used in this study is based on the Moloney ~nurine leukemia 
vim s (MoMuLV). In general, the MoMuLV life cycle begins with virion attachment to a 
specific cell-surface receptor, followed by hsion of the envelope protein and endocytosis 
into the host cell. The RNA viral genome is reverse transcribed to a linear duplex of DNA 
within the virion core and transferred into tire host cell's nucleus while still associated with 
virion proteins. Viral DNA is integrated at random sites in the host's genome to form the 
provin~s. Replication-competent viruses have genes which code for the viral proteins: 
gag7 p { j ,  poi, and errv which are required for the synthesis of viral particles. The ir,t gene 
product of the pol region mediates the integration of proviral DNA into the genome of the 
host. The viral genome is then synthesized from the 5' LTR region to the 3' I,TR region. 
'The 5' LTR i s  recognized by the host's cellular transcription machinery and acts as a 
promoter for the viral genome usitlg the host's RNA polymerase 11. The full-length RNA 
transcxipts are fated for the new viral genome or are processed to rnKNAs for gag, pro, 
and pol, and env viral proteins. Finally. virion proteins are svnthesized, and along with the 
RNA genome, assembled into capsids Replication-competent viruses produce infectious 
particles which bud from the host cell and undergo m h e r  rounds of host cell infection 
(Miller, 1990; Figure 2). 
Figure 2. Replication cycle of retroviruses (adapted from Fields et al., 1996) 
Retroviral vectors have been engineered for safety, to be replication-incompetent. 
The use of replication-competent viruses could result in multiple random integration of 
viral DNA into the host genome. The random integration could disrupt normal gene 
expression or activate oncogenes (Varmus et al., 198 1). Moloney murine leukemia virus 
has been recombined to generate a replication-incompetent retroviral vector by 
separating from the retrovirus, partially or completely, cis-acting viral genes needed for 
the production of infectious particles. The remaining 5' LTR, Y?+ packaging signal, and 
3' LTR proviral DNA are recombined into a plasmid backbone. The structural proteins 
that would have been provided by the retroviruses' own genes are supplied in trans by 
"packaging cells" to generate virions. The viral regulatory sequence present in the 5' 
LTR, or an independent promoter, for example the CMV or SV40 promoter, subcloned 
into the retrc~viral vector may be used to express a therapeutic gene of interest. In 
addition, the viral vector may also contain antibiotic selection markers which allow for 
identification of infected clones or enable the generation of populatiorls of cells which 
consist entirely of transduced cells (Eglitis and Anderson, 1988). For example, an 
ampicillin resistance gene is often used for selection in prokaryotic cells, while the 
rieolnycin resistance gene confers resistance to G4 18 in eukaryotic ceils (Miller et ai., 
1988). 
Retroviral packaging cell lines 
Packaging cell lines have been engineered to provide structural proteins needed to 
generate virions for ieplication-incompetent retroviral vectors. Complementary gag-pol 
and em) coding regivns were incorporated into NIW3T3 mouse fibroblast cells to generate 
packaging cells capable of producing infectious particles by supplying the viral proteins 
needed for the production of infectious particles which had been partially or totally 
removed from the retrovirus. The resulting CP+E-86 ecotropic host range cell line and 
PA3 I7 amphotropic host range cell line provide the viral structural proteins in ~ Y L N ~ S  SO 
that ir~fectious particles can be produced only within the packaging cell line (Miller and 
Huttimore, 1986; Danos and Mulligan, 1988). 
Two packaging cell lines fisve been employed in this study in order to minimize the 
potential for the development of replication-competent retroviraf particles and maximize 
the potential for production of high-titer vector producing ceils (Markowitz et a l ,  1988) 
GP+E-86, which initially receives the recombinant plasmid, was designed to separate the 
gag-pol genes from the env gene as an additional barrier to the formation of 
Figure 3. Recombinant retroviral plasmid transfected into a packaging cell line resulting 
in the production of virions (adapted from Ausubel et al., 1996) 
replication-competent retroviruses (Figure 3). Because this packaging cell line has an 
ecotropic host range, virions produced by W+E-86 are not capable of infecting human 
cells. In order to produce virions capable o f  infecting human cells, viral supernatant 
produced by GP+E-86 cells is used to transduce PA3 17 cells. The production of virions 
using two packaging cell lines will increase the production of virions and also benefit 
from the added safety barrier to replication-competent retroviral infection. 





United States Biologicals) and all four deoxgnucleotides. DTT (7.7mM, Gibco BRL); 
dNTP (dATP, dCTP, dGTP, and dTTP, each at a final concentration of 0.77 mM; Gibco 
BRI,), and 3.25 units of T7 Sequenase enzyme, diluted according to  the manufacturer's 
protocol in 1.7 pl of 50 mM Tris-HC1 pH 7.5 ,  and 10 rnM 2-mercaptoethanol, final 
volume 26 p1. 'This reaction was incubated at RT for six min. The enzyme was then heat- 
inactivated at 75OG for three min. This resulted in the double-stranded DNA for the opal 
arginine suppressor tRNA gene insert subcloned into the pLNXpLl plasmid (Figure 4). 
Figure 4. I3ouhle-stranded DNA for the opal arginine suppressor t RNG gene subcloned 
illto the pLNXpL1 plasmid. 
I'he ends of the double-stranded DNA were prepared for subcloning into the 
retroviral vector by digestion with restriction endonucleases Xho I and Hind I I .  50 mM 
Tris-HCi pE18.0, 10 d+d MgCI,, 50 mM NaCI, 2.5 units cf )find 111 (Gibco BRI,), and 25 
units ofXho 1 (Gibco BRL) were added to the double-stranded DKA synthesized in the 
fill-in reaction, final volume 50 ~ d .  The reaction mixture was incubated in a waterbath at 
37oC for two h: The digested opal arginine tRNA gene insert was transferred to a 
Chroma Spin+TE-30 column (Ciontech) to remove unincorporated nucleotides and small 
oligonucleotide fragments using the manufacturer's protocol 
The DNA was ethanol precipitated as described by Sambrook et al., 1989. in 
brief, the volume of DNA in buffer recovered from the Chroma Spin+TE-30 column was 
measured. TWO volumes of ice-cold 100% ethanol, 0.1 volume of 4M ammonium 
acetate, and 0.0 1 volume of 20 mgiml glycogen was added to the DNA recovered from 
the Chroma Spin column. This mixture was placed into the -700C freezer for 15 min to 
precipitate the DNA. The mixture was centrifuged at 12,000 X g for 15 minutes and the 
supernatant poured off 200 p1 of ice-cold 70% ethanol was carehlly added so as not to 
disturb the pellet, and immediately poured off 200 pl of ice-cold 95% ethanol was added 
and immediately poured off The pellet was allo~ved to air. dry briefly, then resuspended in 
100 1.11 W buffer. I p1 of resuspended DNA was added to 99 pl of TE, pipetted into a 
100 pl cuvette and quantitated by spectrophotometer (Beckman DU Series 500) reading 
at OD2nci using the manufacturer's protocol. 
The pLNCX retroviral vector (Clontech) was modified to remove the CMV 
promoter and introduce a polyli~~ker containing multiple cloning sites (kind gift of Robert 
Mandeli). The resulting plJNXpLi vector was used in this study. Because eukaryotic 
tRNAs are known to have a split intragenic promoter (Sharp et al., 1985), the pLNXpLl 
retroviral vector should demonstrate tRNA gene expression without an extragenic 
prornoter. 
pLNXpLl plasmid was digested with .fro I and Hitld 111 to open the plasmid and 
generate ligation sites compatible with the opal arginine tRNA gene insert. pLNXpL1 
plasmid DNA (5 pmol), 50 tmM Tris-HC1 p H  8.0, 10 mhl MgCI,, 50 mNI NaCi, and 25 
units of each Xho 1 and Hind 111, final volume 50 pl, were incubated in a water bath at 
37% for two hr. The digested plasmid DNA was electrophoresed over 1% low melting 
point (650C) agarose (Sigma) in i X TAE (0.04 M Tris-acetate, 0.001 M EDpTA, pH 8.0). 
The band corresponding to 585 1 bp was cut from the gel and quantitatively transferred to 
a SPIN-X 0.22 prn cellulose acetate centrifkye filter (COSTAR) using 200 p1 TE buffer. 
ft er centrihgation at 10.000 X g for three minutes, the DNA was ethanol precipitated as  
described previously, resuspended in 20 pl TE butyer. The quantity of DNA was 
estimated hy comparing the relative band density of 1 p1 1 Kb DNA ladder (1 pg/pl, 
Gibco BRL) to a 2 p1 plasmid DNA sample after both had been electrophoresed on a 1% 
low melting point agarose gel prepared with 1X TAE. 
The gene insert was ligated into the pLNXpLI vector using T4 DNA ligase 
enzyme and reagents accompanying the enzyme (New England BioLabs, Inc.). The 
reaction mixture containing 100 ng digested pLNXpLI plasmid vector, a five-fold molar 
excess of opal arginine tRNA gene insert, 50 mIcl Tr-is-IIC1, 10 mM MgCl,, 1 mM ATP, 
25 mglrnl BSA, and 400 units T4 DNA ligase enzyme, reaction pH of 78 ;  final volume 10 
pl. This mixture was ligated overnight in a 14% water bath. The ligation mixture was 
then used to transform E. COIL as previously described in this manuscript. 
Screening of bacterial colonies for plasmids containing suppressor tRN/h 
Recombinant plasmids were screened by ~lsing restriction enzymes to digest the 
plasrni J fragment which contained the multiple cloning site and suppressor tRNA gene 
insert. 'To screen for plasmids containing suppressor tRNA, individual bacterial colonies 
were picked from the LB-ampicillin plates, innoculated into 5 ml aliquots of LB-ampicillin 
medium (250 ,ug/ml), and incubated overnight at 37OG in a bacterial shaker. Plasmid 
DNA was isolated using the Wizard Plus miniprep purificatior~ kit (Promega) following the 
manufacturer's protocol. Each DNA miniprep was digested with 10 units K I ~  I (Gibco 
BRT .). 10 units Xho I (Gibco BRL), 3 5 mM Tris-HCI pH 7.7, 7.5 mM MgCl,, 25 mM 
NaCl, and 25 mM KCI, final volume 20 p1. The reaction was incubated for two hr at 
370C in a water bath. Digested DNA samples were electrophoresed on a I %  low melting 
point agarose gel in 1X TAE at l0OV for 45 min. The gel was stained with ethidium 
bromide by immersing the electrophoresis gel into a solution of 50 pg ethidium bromide in 
500 ml TAE buffer, fot- I S  min. The gel was removed from the staining solution, placed 
on a 365 nm UV light box (Fotodyne) and photographed. The electrophoretic banding 
patterns were inspected to determine the presence of bands corresponding to a base-pair 
size equivalent of the region of the plasrnid multiple cloning site and opal arg suppressor 
tRNA gene insert. Plasniid clones which contained the suppressor tRNA gene insert 
would have restriction digest fragments approximately 100 bp larger than fragments from 
plasrnid clones without the gene insert. Those DNA plasmid clones bearing plausable 
suppressor tRNA gene inserts were selected for assessment of the functional activity of 
the suppressor tRNA. 
Assay for functional activity of  suppressor tRNA 
Gontructio~l of' mhRGFP reporter gene . An opal mutation was introduced in the 
hulnanized red-shified green fluorescent protein (hKGFP) gene by polymerase chain 
reaction. 'The arginine codon at amino acid position 73 in the hRGFP gene was changed 
to an opal stop codon (UGA) and subcloned into a pHE700 vector (pHE700 Arg73opal 
mhRGI:P, kind gift of Rekha Panchal) 
In order to subclone the mhRCrFP gene into a pLNCX retrovlral vector, the gene 
was excised from the pHE700 vector by a two-step digestion. i n  the first step, the 
pHE7OO vector was digested with the ~ V o t  1enzyme. A reaction mixture containing 10 pg 
pHE700arg73opal W F P  plasmid DNA, 50  mM Tris-HC1 pH 8.0, 10 mM MgCi,, 100 
mN1 NaCI, and 30 units of Not I. final volume 20 p1. was incubated 2 hr at 370C. 
The overhanging nucleotides were filled-in using a reaction mixture containing T7 
DNA polymerase enzyme (Sequenase Version 2, Urrited States Biologicals) and all four 
deoxynucleotides. 'The reaction mixture contained DTT (7.7mM7 Gibco BRI,); dNTP 
jdATP, dCrTP, dGTP, and dTTP, each at a final concentration of 0.77 nuM; Gibco BRL,), 
and 3 2 5  units of T7 Sequenase enzyme, diluted according to the manufacturer's protocol 
in 1 .7 p1 of 50 mM Tris-HC1 pH 7.5, and 10 mM 2-rnercaptoethanol, final volume 26 p1. 
The linearized plasmid was subseyuel~tly digested in a mixture containing 50 mM 
Tris-HCl pH 8.0, 10 mM MgCI,, 50 mM NaCI, and 20 units of Hind III, final volume 50 
pl, and incubated two hr at 37% The digested fragments were gel purified by 
electrophoresis on a 1% low melting point agarose gel prepared with 1X TAE to separate 
the rnhRGFP gene insert from other digestion fragments Only one 737 hp band, 
corresponding to the size of the mhRGFP gene, was cut from the gel and purified using a 
SPIN-X 0.22 mm cellulose acetate centrifuge filter (COS'TAR). The rnhRGFP gene DNA 
fragment was ethanol precipitated as previously described, and resuspended in 2 0 ~ 1  TE. 
Ketroviral pl,NCX plasmid (Clontech) was prepared for subcloning the m W P  
gene by first digesting it with 20 units of ('la 1 in a reaction mixture containing 50 mM 
Tris-FICI pH 8.0, arid 10 mM l\/IgCI,; final volume 20 pi, and incubated at 3 7OC for two 
hr The overhanging nucleotides were filled-in as previously described. The linearized, 
blunt-ended pLNCX vector was gel purified, and ethanol precipitated. The cut ends of the 
linearized plasmid were prepared for ligation by digestion in a mixture containing 50 mM 
7'ris-HCi pH 8.0, 10 mM MgCl,, 50 n M  NaCl, and 20 units of Hind 111, final volume 50 
111, and incr~bated two hr at 370C:. 
The digested mhRGIT fragment was ligated to the linearized p%NCX (Clontech) 
using; T4 DNA ligase and reagents accompanying the enzyme (New England BioLabs, 
Inc.) using overhanging end of the Hind III site and the blunt end generated by the fill-in 
of the i'la I restriction site. The reaction mixture containing 100 ng digested pLNCX 
plasmid vector, a five-fold molar excess of rnhKGFP gene insert, 50 mM Tris-HC1, I0 mM 
MgC12. 1 mM ATP, 25 mdml BSA, and 400 units T4 DNA ligase enzyme, reaction pH of  
7.8, final volume 10 p1, was ligated overnight in a 14OC water bath. The recombinant 
plasmid, pLNCX mNIWP, was used to test thefiunctional activity of opal arg tRNA 
(Figure 5 ) .  
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Figure 5. The linearized arg73opal mhRGFP reporter gene was subcloned into the 
retroviral vector pLNCX to generate the recombinant plasmid pLNCX rnhRGFP used to 
establish functional activity of opal arginine suppressor tRNA. 
Testing for functional activity of suppressor tRNA. Plasmid DNA with a plausible 
opal arginine suppressor tRNA gene insert and pLNCX arg73opal mhRGFP were 
cotransfected into XP12ROSV cells. A combination of suppressor tRNA and mIiRGFP 
DNA was used for the cotransfection. Cells cotransfected with functional gene inserts 
would be expected to exhibit green fluorescence. 
XPI2ROSV cells were seeded into 6-well culture plates (Falcon) at 2 X 105 cells 
per 35 mm well, a density sufficient to generate a 50% confluent surface in 24 hr. Each 
cohansfection reaction consisted of I0 pl suppressor tRNA miniprep plasmid DNA, 2 pg 
pLNCX arg73opal mhRGFP, 6 pl FuGENE 6 transfeetion reagent (Boehnger 
eim), and 94 p1 OptiMEM (Gibco BRL). At 24 and 48 hours, the medium was 
removed from the wells of the culture plate and replaced with 2 ml HBSS. The 
cotransfected cells were observed at 100 X magnification using a Diaphot 300 
fluorescent microscope (Nikon) illuminated with a 488 nm light source. GFP-positive 
cells, visible as bright green cells, indicated which plasmid clones contained functional 
opal arg tRNA. The recombinant retroviral vector containing functional *a1 arginine 
suppressor tRNA was designated pLNXpLl OAT (Figure 6). 
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Figure 6. The synthetic opal arginine suppressor tRNA gene was subcloned into the 
pLNXpL 1 retroviral vector to generate the recombinant plasmid pLNXpLl OAT. 
Large scale production of the recombinant pLNXpLl OAT plasmid DNA 
DH I OH E. coli competent cells, transformed with recombinant plasrnid constructs 
with functional suppressor tRNA, were incubated at 370C overnight in a bacterial shaker 
in 500 rnl LB-ampicillin (100 pg/ml) medium. Plasrnid DNA was purified using a 
QlAGEN plasrnid Maxi kit following the manufacturer's protocol. To ensure the quality 
of the maxiprep plasrnid DNA, samples of the maxiprep DNA and the corresponding 
miniprep DNA were compared by electrophoretic patterns of restriction-digested DNA 
fragments, and verifted by a hnctional activity assay for suppressor tKNA. 
DNA sequencing of plasmid DNA constructs 
DNA sequencing of recombinant plasmid DNA was performed by the DNA 
Sequencing Facility at Iowa State University, Ames, IA. 
Transfeetion of GP-t E-86 ecotropic packaging cell lines 
GP+E-86 packaging cells at passage 7 were seeded into 6-well plates at 2 X lo5 
cells per 3 5 mm well. pLNXpL I OAT7 and pLNSpL i OAT8 were transfected into 
separate wells using 4 pg plasmid DNA and 12 1~1 Fugene 6 in the manner previously 
described. Transfection medium was aspirated from the GP+E-86, the cells were washed 
with 2 in1 H R S S ,  and the medium replaced with 2 mi complete D-I\/LEM. After 24 hr, the 
viral supernatant was used to transduce PA3 17 cells. 
Transduction of PA317 amplrutropie packaging cells 
PA3 17 target packaging ce!ls at passage 7 were seeded into separate 6-well plates 
1 X I O5 cells per 35 rnm well, resulting in approximately 50% confluent cell growth After 
24 hr, the PA3 1 7 cells were transduced using the viral supernatant from Gl?+E-86, as 
previously described, for a total of six transductions. 'Twelve hr after the last transduction, 
the medium over the PA3 17 cells was removed, the cells were washed with 2 rnl HBSS, 
and the medium replaced with 2 ml complete D-MEM plus W18 (1mgJml). Cells were 
incubated in complete D-hllEM plus G418 until no viable cells were detected in 
nontransduced PA3 17 cell wells (negative control), usually five to eight days. 
Transduction of XP12ROSV human target cells 
PA3 17 packaging cells producing recombinant pLNXpL 1 OAT7 and pLNXpLl 
OAT8, and X P  12ROSV target cells were seeded into separate 6-well plates at 1 X 1 O5 
cells per 3 5 rnm well, to generate a population of cells at 4040% confluence in 24 hr. 
Transduction and selection of the XP I2ROSV target cells were perforn~ed as described 
above for establishing the PA3 17 packaging cells. 
Viral titers 
Viral titers, a bioassay, were performed to determine the presence and indicate the 
quantity of infectious particles produced in the supernatant of the PA3 17 packaging cell 
lines transduced with plasmids containing the suppressor tRNA gene insert (Cepko et al., 
1996). IGROV human ovarian carcinoma cells were seeded into 6-well plates at 2 X lo5 
cells per 35 mrn well. PA3 17 vector producing cells were grown to 95% confluence in 
T8O culture flasks (Nunc) Medium was removed from the PA3 17 vector producing cells 
and replaced with 10 ml fresh complete D-MEM. After 24 hr, viral supernantant was 
removcd from PA3 17 cells and centrifuged 10 min at 3000 X g to pellet any PtY3 17 
packaging cells. The supernatant was carefully removed to avoid pellet cells, and diluted 
to 1/10, 1 / I  00, 1 /1000, and 1/ 1 0000 using complete DmM. Protarnine sulfate, 10 
pg/ml, was added to the serial dilutions of supernatant. Triplicate wells of IGROV cells 
were used for each serial dilution. Culture medium was removed from the IGROV cells 
a d  replaced with 1 ml diluted supernatanticomplete D-mr,W/protamine sulfate. IGROV 
cells were incubated at 37% for 24 hr. The medium was aspirated from the IGROV cells. 
IGROV cells were washed with 2 rnl HBSS and the medium replaced with 2 ml complete 
D-MEM plus G4 18 (I mg/ml) 
IGROV cell colonies were allowed to grow for seven days with one change of 
colnplete D-l!dEM plus G418 (1 mdml). The medium was aspirated from the ICrROV 
cells. IGROV cells were washed twice with 2 rnl KBSS. The ZGROV cells were fixed 
and stained by adding I ml of I % methylene blue (Sigma) dissolved in 100% methanol, 
and incubated for 30 min at RT. Excess stain was washed from the IGROV cells by 
inverting the plates under a gentle stream of deionized water, and the plates were allowed 
to dry. 
Colonies of IGROV cells containing more than 40 cells were counted as a colony- 
forming unit (cfu) Dilution sets having between 20 and 120 colonies were counted. The 
lGROV colony counts were averaged for the triplicate wells at each dil-iition, then 
tnultiplied by the appropriate dilution factor to generate the report of cfii/rnl of viral 
superr~atant. Appropriate controls included nontransduced ICrKOV cells (negative 
control), and lGROV cells transduced with supernatant of known viral titer (positive 
control). 
Multiplicity of Infection (MOI) is determined by dividing the number of cfb by the 
number of cells being transduced. This measurement can help to establish how much viral 
supernatant would be needed to transduce a quantity of cells under optimal conditions 
(Cepko, 1996). 
RNA was isolated using the single-step guanidinium acid-phenol method (Krieg, 
1996; Chomczynski and Sacchi, 198'7). All glassware and equipment were RNase 
decontaminated before starting by an additional wash in RNase Free (Continental 
Laboratory Products) and rinse with DEPC-treated water (0.2 ml DEPC to 100 ml 
double-deionized H20). In addition, all glassware and equipment was handled with gloved 
hands, and work was performed quickly (Gilman, 1994). All reagents were made using 
autoclaved, DEPC-treated, double-deiorlized IIzO to avoid RNase contamination. 
Transduced cells were seeded into a 150 rnm culture plate and grown to an 
estimated 1.8 X 1 O7 cells. Medium was aspirated from cell c~~ltures and the cells were 
lysed with 2 rnl denaturing solution (4 M guanidine thiocyanate, 25 mM sodium citrate, 
0.5% Sarkosyl, and 0. I M 2-mercaptoethanoi). The lysate was passed seven times through 
an 18 gauge needle attached to a 5 rnl syringe. 0.2 ml of 2 M Sodium acetate, pH 4, was 
added to the homogenate and vortexed 20 sec  2 rnl water-saturated phenol (100 g phenol 
ciystals dissolved in 100 ml distilled H20 at 60-65 OC)  was added and the mixture 
vortexed 20 sec. Subsequently, 0.4 rnl of 49: 1 chloroforrn/isoarnyl alcohol was added and 
the mixture vortexed 20 sec The mixture was incubated 15 minutes over ice, then 
centrifuged 20 rnin at 10,000 X g at 40C. The aqueous phase was then transferred, by 
pipette, to a clean test tube. RNA was precipitated by adding 2 rnl of 100% isopropanol. 
Samples were incubated 30 min at -200C, centrifhged 10 min at 10,000 X g, 40C7 and the 
supernatant was discarded. The RNA pellet was dissolved in 0.6 ml denaturing solution 
(4 M guanidine thiocymate, 25 mM sodium citrate, 0.5% Sarkosyl, and 0.1 M 2- 
mercaptoethanol), precipitated with 0.6 ml of 100% isopropanol for 30 rnin at -200C, 
centrifuged 10 rnin at 10,000 X g, 40C, and the supernatant was discarded. The RNA 
pellet was resuspended in 0.6 111175% ethanol at RT, vortexed 20 see, incubated 15 
minutes at RT, and centrihged five rnin at 10,000 X g, 40C. The supernatant was 
discarded and the RNA pellet allowed to air dry. RNA was resuspended in 100 p1 DEPC- 
treated water and quantitated by spectrophotometric measurement. I pl of resuspended 
DNA was added to 99 ~d of TE, pipetted into a 100 ~l cuvette and quantitated by 
spectrophotometer (Beckman DU Series 500) reading at ODzso using the rnanilfacturer's 
protocol. 
Samples were denatured using 10 pg total RNA and three volumes of denaturing 
tnix consisting of 500 pl formamide. 1 62 pl 1 2.3M formaldehyde. and 1 00 ld MOPS 
butfer [Q. 2 M 3 -(N-morpholin0)-propanesuIfonic acid, pH 7.0, 0.5 M sodium acetate, 0.0 1 
M EDTA]; and incubated 15 rnin at 650C. Two volumes of ice cold 20X SSC (175 g 
NaCI, 88.2 g sodium citrate, bring the volume to I liter wit11 H20, pH 7 )  was then added 
to each RNA sample. The samples were kept on ice until they were loaded into the 
manifold. A Nytran Plus membrane, pore size 0.45 prn (Schleicher & Schuel), and 
Whatman filter were cut to size, premoistened in DEPC-treated water, and soaked in 20X 
SEX' For 30 min. The prepared Nytran Plus membrane and Whatman filter were then set 
into a SlotBlot model PR648 manifold (Hoefer Scientific Instruments) according to the 
na~uufacturer's directions. Each well was prefilied with 500 pl LOX SSC and drawn 
through at a rate of 10 rnin per rnl  Prepared samples were then added to the wells and 
allowed to filter through the membrane. Empty wells were filled with 1 ml of 1 OX SSC. 
After samples wells were emptied, 200 1.~1 I OX SSC was added twice and allowed to filter 
through the membrane. The vacuum was discontinued, the manifold disassembled, and 
the membrane carried between two Wtlatman filters f i r  immediate crosslinking in the UV 
Stratalinker 1800 (Stratagene) using the autocrosslink setting. The membrane was soaked 
briefly in 200 1111 2X SSC then prehybridized eight hr or overnight at 42OC in 10 ml 
Hybri sol 1 (50% formarnide, 10% dextral1 sulfate, and 1% S3S;  Oncor, Inc.). 
Opal Arg tRNA probe: 
.4 probe for the opal arginine tRNA was constructed using the double-stranded 
suppressor tRNA gene insert as a template A primer, RE36 5' cgagaaaacgaaccccacttaacc 
3 ' ,  consisting of the first 24 nucleotides of the antisense strand was used to generate a 
radiolabeled strand complementary to the opal arginine tWA.  The double-stranded DNA 
was denatured by heating 30 pmol DNA at 1000C for 10 min and immediately cooled on 
ice A radiolabeled strand was synthesized in a reaction containirlg 150 pmol BB6 pfimer; 
dATP, dGTP, and dTrTP i :  I I mixti~re, 0.05mM; 50 pCi ju322y dCTP (~rnersham),  and 4 
units of Klenow enzyme and reagents accompanying the enzyme (Boehringer Mannheim); 
0.5 M Tris HCI pH 7.5; 0. l M MgCI,; 10 mM DT'T; 0.5 rng/ml BSA, adusied to a final 
volume of 25 pi with TE The mixture was incubated 30 rnin at 37OC, and the reaction 
stopped by heating to 650C for 10 min in a heat block. The probe was ethanol 
precipitated to remove unincorporated nucleotides and the pellet resuspended in 100 !;I 
TE. I ~ 1 1  of probe bas  added to 4 ml of OptiScint 'HiSafe" scintillation fluid (LKB 
Scintillation Products) in a scintillation vial, and quantitated for 32P activity in a Tri-carb 
2 100TR (Paekard) scintillation counter using a direct reading of 32P activity. The 
radiolabeled probe was added to 10 rnl Hybrisol I (Oncor, inc.) at a concentration of at 
least 1 X 106 cpidml of hybridization solution. 
Hybridization of probe to RNA samples on Kytrrn membranes 
Nytran membranes with total RNA samples were prehybridized with 10 in1 
Hybrisoi I solution for eight hr or overnight at 420C in a rolling hybridization cylinder 
(Hybridizer 700, Stratagene). The prehybridization mixture was removed and replaced 
with 10 ml of radiolabeled probe in Hybrisoi I, Membranes were then hybridized eight hr 
or overnight at 42OC. 
Membrane washes and autoradiography 
I-lybridized membranes were washed twice for five min using 250 mi 2X SSC and 
0.1% SDS at RT on a shaking bath. A third IS min wash using 250 rnl O.1X SSC and 
0 .  I % SDS at 57% in a shaking water bath was sufficient to remove any ur~bourld probe. 
Membranes were briefly rinsed in 250 ml 2X SSC. wrapped in plastic film, and 
autoradiot.,>raphed for- 24 hr at -70°C using a 32P intensifying screen (A-uttoaadiography 
Cassette FBXC 8 10. Fisher Biotech). 
Restoratioa of functional activity of  pLNCX mhRCFP gem 
To demonstrate fiinctional correction ofthe arg73opal rnhRGFP gene, 
X P  I2KOSV cells expressing the rnhKGFP gene were transduced with the suppressor 
tKNA gene. To introduce the mutated hRGFP first, 2 X lQ5 XP12ROSV cells were 
seeded into a 35 rnm well. The cells were transfected overnight using 4 pg of rnN(GFP 
DNA and 6 p1 FuGENE 6. The transfection medium was aspirated, and the XP I2ROSV 
cells were washed with WBSS. The XP12ROSV cells were incubated in 2 mi complete D- 
M E M  for 24 hr and then selected with 2 rnl complete D-MEM containing G-4 1 Y (1 00 
mgiml) until selection was complete in the negative control (nontransfected XPI2ROSV 
cells ) wells and XPI 2ROSV cells transfected with mhRGFP began to proliferate in 
complete D-MEM with G-4 1 8. The neomycin-selected population of XP 12ROSV cells 
was then transduced with viral supernatant from PA3 17 cells containing pLNXpL1 OAT7 
or pLNXpL1 OAT$. 
The SiP I2ROSV cells, transfected with mhRG-FP and transduced with either 
pL,NXpLI OAT7 or pLNXpL1 OAT8, were observed for GFP fluorescence. The 
medium was removed from the wells of the culture plate and replaced with 2 ml KBSS in 
each 35 mrn well. The cultured cells were observed at 100 X magnification using a 
Diaphot 300 fluorescent microscope (Nikon) illuminated with a 488 nrn light source, 
GFP-positive cells are easily visible as bright green cells. 
RESULTS 
Sequence verification 
Sequence data revealed that two forms of opal arginine suppressor tRNA genes 
had been subcloned into pLNXpLI. pLNXpLl OAT8, contained the synthetic suppressor 
tRNA gene inserted in the vector without any additional nucieotides or deletions. The 
second clone, pLNXpLl OAT7 contained a tandem repeat of the gene insert without any 
additional nucleotides between the pair of suppressor tRNA genes. Both inserts were 
oriented in the vector in the same direction, 5' I to 3' Hir~d 111. Both recombinant 
plasmid clones were used in this study. 
Production of infectious particles 
Virion production by packaging cells is measured by means of a viral titer 
bioassay. The results allow one to determine the amount of virus used in experiments and 
also identify cell lines with high viral titer. The viral titer is reported as colony forming 
units per 1x1 of supernatant (ckiml), a measure based on the production of a selectable 
colony of cells. The viral titer is considered a rough quantitative means where titers within 
a factor of 3 are considered similar due to variation in the number of cell. divisions which 
may occur after viral integration and before the addition of selective media If greater 
accuracy is needed, the viral titer bioassay should be performed multiple times and the 
results averaged (Cepco, 1905). In this study, viral titer was used to indicate the presence 
of infectious particles containing the neomycin-resistance gene subcloned with the 
suppressor tRNA gene. Viral titers would indicate that transfer and expression of the opal 
arginine tKNA would not adversly affect the production of virions by readthrough of 
normal stop codons. 
Multiplicity of Infection (M01), determined by dividing the number of cfb by the 
number of cells being transduced, can help establish how much viral supernatant would be 
needed to transduce a quantity of cells. A mixed population (cells transduced but not 
cloned) of PA3 17 packaging cells producing virions from pLNXpLl OAT8 were reported 
to have a viral titer average of 5,3 3 X 1 O4 cWml of viral supernatant, and pl,NXpL 1 
OAT7 were reported to have a viral titer average of 1.8 X 1 OQcfu!ml of viral supernatant. 
The XP 12ROSV human target ceils, were plated at 1 X 1 O5 cells per 3 5 mrn well and 
transduced with supernatant six times over three days. Transductions using PA3 17 
producing virions from pLNXpLl OAT8 would have been over one MOI(5.3 X 1 Q4 cfu/ 
1 X 1 Q5 cells = 1.59 M01). Transductions using PA3 I 7 producing virions from 
pLNXp1,l OAT7 would have had considerably less than one MOI (5.4 X 103 cfiu' 1 X 1 Q5 
cells - 0054 MOI). 
Expression of the suppressor tRNA 
Slot blots. To determine the expresson of suppressor tRNA in PA3 17 packaging cells and 
XPI2ROSV human target cells, the slot blot was probed with "2P-labeled oligonucleotide. 
Expression of the suppressor tRNA was obsenied in both PA3 17 (Figure 7) and 
XP 12ROSV target cells (Figure 8). 
pZ,NXpL. I OAT 8 
trailsfection 
pkXSN 
vector on1 y 
pLNXpl. 1 
vecjor only 
pLNXpk 1 OAT 7 
pl,NXpL 1 OAT 8 
Figure 7. Slot blot showing opal arginine tRNA detected by the radiolabeled probe in 
total RNA samples from transduced PA3 17 packaging cells. The left column contains 
control RNA samples. pLNXpL1 OAT8 is the positive control obtained from PA3 17 cells 
transfected with the pLNXpLl OAT8 plasmid. pHE700 arg tRNA is a negative control 
for probe specif city and demonstrates that the probe used in this study was sensitive to a 
single base pair change corresponding to the nucleotide change in the anticodon of arg 
tRNA (UCG) to the anticodon of opal arg tRNA (UCA) and specific for the opal arg 
suppressor tRNA. pLXSN and pLNXpLl are negative controls for plasmids without opal 
arg tRNA gene inserts. The right column contains study samples of RNA kom PA3 17 
cells transduced by GP-tE-86 packaging cells producing virions from recombinant 
plasmids with opal arg tRNA gene inserts. pLXSN OAT5 is a recombinant plasmid 
containing an opal arg tRN A gene insert identical to pLNXp1, l OAT8 and shows similar 
expression of the gene without regard to piasmid vector. pLNXpL l OAT7 contains a 
complete tandem repeat of the opal arg tRNA gene insert. pLNXpLl OAT8 contains a 
single copy of the opal arg tRNA gene insert. pLXSN OAT5, p1,NXpL i OAT7 and 
OAT8 all demonstrated expression of the opal arg tRhrA gene insert. 
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Figure 8. Slot blot showing opal arginine tRNA detected by the radiolabeled probe in total 
RNA wmples from XP 12ROSV human target cells transduced from PA3 17 packaging 
cells. The left column contains total RN A from control samples. pHE700 arg tRNA is a 
negative control for probe specificity No probe signal was detected from the RNA of 
XP12ROSV cells transfected with a vector including the gene for arg tKNA. pLNXpL1 is 
a negative control for cells transduced from PA317 producing virions from plasmids 
without the opal arg tRNA gene insert. pLNXpLl OAT8 transfection is a positive control 
for opal arg tRNA expression. The top two samples of the right column contains total 
R N A  samples from XP12ROSV cells transduced by PA3 17 producing virions from 
recombinant plasmids with the opal arg tRNA gene insert. Opal arg tRNA expression is 
evident in X P  12KOSV cells transduced with virons from both pLNXpLl OAT7 and 
pLNXpL1 OAT$. NV, a negative control, is a total KNA sample from XP12ROSV cells 
that have not been transfected or transduced. 
Results indicate GP+E-86 and PA3 17 vector producer cells were able to produce 
virions from the recombinatrt plasmids pLNXpLl OAT7 and pLNXpL I OAT8 containing 
the opal arg tRN A gene insert. GP+E-86 and PA3 17 vector producer cells successfillly 
delivered the suppressor tRNA gene to human target cells. XP 12ROSV cells transduced 
by virions from the recombinant plasmids pLNXpLl OAT7 and pLNXpLl OAT8 
translated the opal arg tRN A gene insert as a fUnctional suppressor t RN A. Expression of 
the opal arg suppressor tRNA was not detected in PA3 17, XP12ROSV, and XP12ROSV 
cells or these cell lines transiently transfected with pLNXpL 1 vector which did not 
contain the opal arg tRNA gene insert. PA3 17 and XP12ROSV cells tmnsfected with 
arginine tRNA and selected with hygromycin (a negative control to demonstrate the 
specificity of the radiolabeled probe) did not show any probe signal on RNA slot blots. 
An intense signal was observed in PA3 1 7 and XP I 2ROSV cells transiently transfected 
with pLNXpLl OAT8 (a positive control for opal arg tRNA gene expression). 
Translation of a functional protein from a gene with a nonsense mutation 
To demonstrate successful delivery, expression and suppression of the nonsense mutation 
by the suppressor tRNA; XPI2ROSV human target cells were transfected with the 
pLNCX arg73opal mhRGFP gene, selected with neomycin, and transduced with the 
retroviral supernatant containing the suppressor tRNA gene (Figure 9). 
Figure 9. XP12ROSV human target cells transfected with the mhRGFP gene, selected 
with neomycin, and transduced with pLNXpLl OAT demonstrate translation of 
functional GFP protein. 
Restoration of GFP fluorescence was observed to range from approximately 1 % 
of the cells to only a few isolated cells in a 35 mm well. No fmctional correction of 
rnhRGFP was ever observed in cells transfected with rnhRGFP only, or transduced with 
pLNXpL l OAT only. 
DISCUSSION 
~h~  resent study demonstrates that recombinant retroviral vectors may have the 
poterltial to deliver the suppressor fRNA ggenes to human target cells using currently 
accepted methods Expression of the suppressor tRNA gene was observed in both the 
packaging cell lines and fw-nan target cells. Thus, demonstrating that opal arg suppressor 
tft&M. gene could be packaged into retroviral virions, delivered to the target cells, and 
subsequently expressed with the ability to suppress the nonsense mutation in the mkRGFP 
gene However, the firnctional correction of the mhRGFP was observed in only 1% of the 
transduced XP I 2 RO SV cells and would need to be improved for therapeutic effect. 
The low percentage of functional correction could have been due to a low 
mhRGFP mRNA copy number which has not been studied in this investigative model. 
I,ow mXNA copy number has been associated with nonsense mutations in many 
organisms, however, the role of translation in nonsense-mediated mRNA decrease has not 
been determined in mammalian cells (Buzina and Shulrnan, 1999). In addition, eukaryotic 
release factor I has been shown to compete with suppressor tKNAs at termination codons. 
and thereby generate tmn.cated mRNA which would be translated to truncated, 
nonhnctional protein molecules (Drugeon et al., 1997). 
There are several ways the system investigated in this study could possibly be 
improved The synthetic suppressor tRNA gene could he rederigrled to increase the level 
of expresison by linking - multiple copies of the suppressor tRNA gene in tandem. 'The most 
appropriate retro\?ira1 rector to cany the rnhRGFP gene to a specific tissue could be 
determined. The best vector producer cells could be isolated. Or only those 
sequences with nonsense mutations in a suppression-favorable codon context could be 
studied for therapeutic efficacy. 
Review design of suppressor tRNA gene. The suppressor tKNA gene could be 
redesigned to optimize the expression of the gene and hnction of the tRNA transcript. 
The synthetic suppressor tRNA gene in this study consisted of the structural sequence and 
15 of the 3' base pairs. The arginine tRNA gene should be studied to determine which 
specific regions contribute to optimal expression of the gene and those structural features 
essential for arninoacyl-tRNA synthetase recognition. 
The 5' and 3' flanking sequences have been reported to have a significant effect in 
gene transcription. Arnold and Gross (198'7) reported that the 5' extragenic control 
region between positions of -5 1 and -16 acted as a positive modulator for transcription 
factor binding when expressing human valine tRNA genes. In another study, Tapping et 
al. (1994), detailed how transcription was partially inhibited or initiation redirected if the - 
43 and -46 positions of the human serine tRNA gene were prebound with lac repressor 
'f hey determined that the human RNA polymerase III transcription complex extends at 
least 35 nucleotides upstream to the structural coding region and that this flanking region 
was important in the assembly of the initiation complex. The 3 ' flanking sequence of the 
human valine tRNA gene has a role in stabilizing preinitiation complex formation. Arnold 
et al. (1988)' described distinct roles for the 3' and 5' flanking sequences in a two-step 
mechanism where transcription factor TFIIIC associated with the tRNA and an extragenic 
control region-independent conformational change occurred. 
'The function of the tRNA could be optimized bv assuring the presence of the 
recognition features needed for aminoacyl synthetase interaction. Synthetases, which 
attach amino acids to tRNA, appear to be recognizing elements in the anticodon region, 
the acceptor stem, and the "discriminator base" at position 73 (Saks et al., 1994). Current 
sequences of the arginine tRNA gene and synthetase structures should be reviewed and 
compared to the synthetic tRN A gene. 
Introduce rnore copies of the suppressor tRNA gene. The low level of fbnctional 
correction in the transduced cells relative to the cotransfected cells co~ald ham beer1 the 
result of only a single copy of the tRNA gene integrated into the target cell genome. 
Multiple copies of the suppressor tRNA gene could be subcloned into the retroviral vector 
and thereby improve the level of expression by increasing the number of copies available 
for transcription. Studies should be done to determine the optimal length of the linker 
regions between genes. 
Selection of the appropriate vector. Vectors are continuously being developed to 
includz new markers, a variety of promoters for special needs, conditional expression, and 
species-specific elements. Only one type of retroviral vector system was used in this 
study, so it is possible that another retroviral vector or perhaps an entirely different vector 
system, such as one based on the adenovin~s or lentivirus, may be more suitable for 
suppressor tRNA gene transfer. A retroviral vector was selected for this study in order to 
stably integrate the suppressor tRNA gene into the host DNA, however, it also requires 
mitotic cell division for transduction (Robbins and Chivizzani, 1998). Some current 
applicatior~s t'or retroviral vectors target rapidly dividing cells such as hepatocytes, 
proliferating synovial cells, tumor cells, or ex viva transductions of cells which can be later 
transplanted into a recipient. Therefore, selection of a vector should consider stable gene 
expression and the nature of the target tissue. 
The vector efficiency may also be somewhat impaired by expression of a 
suppressor t W A  gene. At least one investigator has reported difficulty in establishing a 
vector system which would carry an opal suppressor tRNA Capone et al. (1985), 
reported an inability to establish SV40 virus stocks carrying an opal serine suppressor 
A. Their examination of the SV40 DNA sequence indicated that readthrough of a 
UGA stop codon in VP1, a major capsid protein, would produce a protein at least 40 
amino acids Longer. They speculated that the additional protein length interfered with viral 
assembly. Production of infectious particles is essential for gene transfer using retroviral 
vectors. Adequate viral titers and the presence of opal arginine suppressor tRNA in target 
cells would provide evidence that infectious particles were produced and that this 
retroviral vector system had the potential to transfer an opal suppressor tW,Y A. However, 
it may be beneficial to explore alternative vectors for optimal transfer. 
lsolrtio~l of r high-titer vector-producing elone. The transductions in this study were 
made from a mixed population (cells transduced but not cloned) of vector-producing cells. 
Retroviral vectors will randomly incorporate the gene of interest into the host cells' 
genome. it is entirely possible that integration into a key regulatory gene would be lethal 
or debilitating for both packaging cells or target cells. Packaging cells should be cloned by 
limiting dilution in order to isolate an optimal vector producer cell clone. 
Selection o f  appropriate mRNA transcripts. Some rnRN.4 codon contexts will inhibit 
suppressiotl of nonsense codons. Miller and Albertini (1983) studied the efficiency of 
amber suppression in 14 different UGA codons and noted correla+tiio with the first base on 
the 3' side. They determined, with some exceptions, that nonsense codons followed by Ci 
or A were suppressed more efficiently than nonsense codons followed by C or U. In 
addition, secondary and tertiary structure of mRNA surrounding the nonsense codon rnay 
attect the suppression efficiency. In a study examining infectivity and replication 
properties of MoMuLV, a single base change in the sequence flanking the amber codon at 
the gng-pol junction resulted in a change in the secondary structure and thereby affecting 
the translational efficiency. It is also noted that because of this change, a MoMuLV-based 
vector may not be suitable for the transfer of amber suppressor tWA. 
A genes as therapeutic agents. The proposed use of suppressor tRNA 
genes as therapeutic agents may have two advantages over a strategy to introduce a 
normal gene. First, a tRNA gene is relatively small and well within the carrying capacity 
of retroviral vector systems. Many genes are much larger than the typical size of the 
retroviral genome. Genes transferred by retroviral vectors would be limited to 
approximately 1 1 kb. Second, natural tRNA genes are expressed in all  ells because they 
are essential to protein synthesis while protein genes may not be expressed in all cell types. 
Recombinant retroviral vectors, assisted with packaging cell lines, were able to 
transfer opal arginine suppressor tKNA genes into human target cells. T'he transferred 
genes were expressed as suppressor tRNA with the ability to mediate translation of a 
functional protein from a hRGFP gene with a nonsense mutation. However, functional 
correction of rnhRGFP was minimal and will require further study in order to develop a 
system with therapeutic benefit. 
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